The efficacy of lapatinib combined with capecitabine in the treatment of HER2-positive breast cancer

Lapatinib ( Lapatinib), as a small molecule tyrosine kinase inhibitor, plays an important role in the treatment of HER2-positive breast cancer. HER2 (human epidermal growth factor receptor 2)-positive breast cancer is a subtype of breast cancer that is highly aggressive, prone to recurrence and metastasis, and has a high incidence rate among patients. Traditionally, HER2-targeted therapy mostly uses large-molecule antibody drugs such as trastuzumab (Herceptin). However, with the emergence of drug resistance and the increased risk of brain metastasis, lapatinib has become an important supplement as an oral small-molecule drug.

Lapatinib blocks the growth and division of tumor cells by simultaneously inhibiting both HER2 and EGFR signaling pathways, thereby controlling tumor spread. When used in combination with the chemotherapy drug Capecitabine, the synergy between the two can significantly improve anti-tumor activity, especially in patients who have progressed on previous trastuzumab therapy. This combination regimen has been recommended by multiple clinical guidelines for the late-stage treatment of HER2-positive breast cancer, and has unique advantages in controlling brain metastases and systemic diseases.

Compared with traditional monotherapy, the combination of lapatinib and capecitabine shows a stronger ability to overcome drug resistance, and is especially suitable for patients who are HER2-positive, whose disease progresses rapidly, or who have developed brain metastases. In addition, this regimen uses oral administration, which results in higher patient compliance, less impact on quality of life, and reduces the inconvenience caused by intravenous administration.

In foreign markets such as the United States, Europe, Japan and other places, the combination of lapatinib + capecitabine has been widely used in the treatment of HER2-positive metastatic breast cancer. In China, this combination therapy has also been included in the clinical treatment path for breast cancer, and has gradually attracted the attention of more doctors and patients.

Reference materials:https://medlineplus.gov/druginfo/meds/a607055.html